Clinical trial Archives

News and Trends 27 Jan 2023

Psoriasis drug may help treat type 1 diabetes

A large clinical study is now beginning on an approved drug for treating psoriasis. The drug will be tested on patients who were recently diagnosed with type 1 diabetes. The theory is that the drug could preserve the patient’s remaining insulin production. Many hospitals in Sweden are participating in the project, which is funded by […]

January 27, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 27 Jan 2023

Onxeo to study prostate cancer drug

French biotech company Onxeo S.A. has given an update on the clinical development program of its first-in-class drug candidate AsiDNA. Onxeo has activated its first U.S. clinical study site, Next Oncology San Antonio. This phase 1b/2 multicenter, basket trial intends to assess the safety and preliminary activity of AsiDNA in combination with olaparib in patients […]

January 27, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 27 Jan 2023

FDA clearance for ‘revolutionary’ approach to J-Pouch issue

ExeGi Pharma LLC, which develops live biotherapeutic drugs and probiotics, says the FDA has cleared its Investigational New Drug (IND) application for its biologic drug candidate, EXE-346. The clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis (IPAA or J-Pouch) who experience excessive stool frequency. “Excessive stool frequency […]

January 27, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 26 Jan 2023

Orbsen Therapeutics happy with interim diabetic kidney disease study results

Orbsen Therapeutics Limited has announced what it says are encouraging headline interim results from the EU Horizon 2020-funded NEPHSTROM clinical trial for diabetic kidney disease. NEPHSTROM is a randomized, double-blind, placebo-controlled phase 1/2a, trial evaluating the safety, tolerability and preliminary efficacy of an off-the-shelf allogeneic bone marrow-derived mesenchymal stromal cell immunotherapy, ORBCEL, in adult study […]

January 26, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 26 Jan 2023

First patient treated in Atrogi type 2 diabetes clinical study

Atrogi AB, an early-stage Swedish pharma company, has announced that the first patient has been enrolled in a phase 1a/b study. Atrogi’s drug candidate, ATR-258 is a first in class novel b2 adrenoceptor agonist with a unique mechanism of action for the treatment of type 2 diabetes and comorbidities. This approach is supported by data […]

January 26, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 24 Jan 2023

First leukemia patient dosed with SMART101

Smart Immune has announced that the first adult leukemia patient has been dosed with SMART101, a T-cell progenitor cell injection derived from donor stem cells using ProTcell at Memorial SloanKettering Cancer Center (MSK). The phaseI/II trial is a multicenter, open-label, first-in-human study expected to enroll up to 36 adult and pediatric patients with hematological malignancies, […]

January 24, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 20 Jan 2023

DeuterOncology closes financing round to start lung cancer study

DeuterOncology, a clinical-stage drug development company, has closed €5.65 million ($6.1 million) series A financing, to start the phase I clinical study for its lead product DO-2, an improved MET kinase inhibitor currently being developed as a potential best-in-class targeted therapy for lung cancer. The financing included participation from historical investor Newton Biocapital and new […]

January 20, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 19 Jan 2023

Cloned maggot enzyme wound treatment moves closer to reality

Cambridge U.K. biotech company SolasCure, which is developing a wound cleaning technology, has published its pre-clinical results with the International Wound Journal, showing preliminary evidence that supports its new enzymatic debridement product for use in chronic wounds. Debridement, the removal of all infected and nonviable tissue, is a crucial prerequisite for a wound to heal. […]

January 19, 2023 - 2 minutesmins - By Jim Cornall

circulating tumor cells, cancer, clinical trials

News and Trends 19 Jan 2023

Avacta completes fourth dose escalation in tumor study

Avacta Group plc says that AVA6000 continues to show a favorable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial. Additionally, analysis of tumor biopsies obtained from six patients across several cohorts indicates that doxorubicin is being released within the tumor tissue. This confirms the tumor targeting potential […]

January 19, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 19 Jan 2023

GPCR Therapeutics launches multiple myeloma trial

GPCR Therapeutics, Inc., a drug discovery company targeting G Protein Coupled Receptors (GPCR) pairs, has started its phase 2 trial in the U.S. for its lead small molecule asset, GPC-100. GPC-100 targets CXCR4, one of the most prevalent chemokine GPCRs overexpressed in more than 23 cancers. This randomized, open-label phase 2 study assesses the efficacy […]

January 19, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 19 Jan 2023

Pathalys Pharma brings in $150M for SHPT trials

Pathalys Pharma, Inc. and Launch Therapeutics (Launch Tx) have announced a collaboration to advance phase 3 clinical trials for upacicalcet (designated PLS240 for clinical trials) for the treatment of secondary hyperparathyroidism (SHPT) in patients on hemodialysis. Launch Therapeutics is backed by funds managed by global investment firm Carlyle and its life sciences franchise Abingworth. Pathalys […]

January 19, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 17 Jan 2023

Ascletis phase I COVID trial progressing

Ascletis Pharma Inc. has announced the dosing of four healthy subjects in its multiple-dose escalation phase I clinical trial of oral 3-chymotrypsin like protease (3CLpro) inhibitor ASC11 in combination with 100 mg ritonavir tablets for COVID-19. The phase I clinical trial is expected to enroll 72 healthy subjects, including 60 subjects in single-dose escalation cohorts […]

January 17, 2023 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clinical trial

Psoriasis drug may help treat type 1 diabetes

Onxeo to study prostate cancer drug

FDA clearance for ‘revolutionary’ approach to J-Pouch issue

Orbsen Therapeutics happy with interim diabetic kidney disease study results

First patient treated in Atrogi type 2 diabetes clinical study

First leukemia patient dosed with SMART101

DeuterOncology closes financing round to start lung cancer study

Cloned maggot enzyme wound treatment moves closer to reality

Avacta completes fourth dose escalation in tumor study

GPCR Therapeutics launches multiple myeloma trial

Pathalys Pharma brings in $150M for SHPT trials

Ascletis phase I COVID trial progressing

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!